Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Viruses, Band 13, Ausgabe 5, 2021
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Humboldt-Universität zu Berlin
- (wann)
-
2021
- Urheber
-
Weisshoff, Hardy
Haberland, Annekathrin
Krylova, Oxana
Nikolenko, Heike
Göttel, Peter
Dallmann, Andre
Müller, Johannes
- DOI
-
10.3390/v13050932
- URN
-
urn:nbn:de:kobv:11-110-18452/23839-4
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:42 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Weisshoff, Hardy
- Haberland, Annekathrin
- Krylova, Oxana
- Nikolenko, Heike
- Göttel, Peter
- Dallmann, Andre
- Müller, Johannes
- Humboldt-Universität zu Berlin
Entstanden
- 2021
Ähnliche Objekte (12)
Bi- and Multi-specific Antibodies
Identification and characterization of new broadly neutralizing and potent HIV-1-antibodies by Env-specific B cell sorting
The dual aptamer approach : rational design of a high-affinity FAD aptamer
Development of conformation specific Amyloid-beta antibodies
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Humans naturally acquire cross-specific anti-glycan antibodies
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neutralizing antibodies as tools for structure-based vaccine design
Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Development of conformation specific Amyloid-β [Amyloid-beta] antibodies
Protection from cytomegalovirus infection by glycoprotein-specific monoclonal antibodies
Bi- and Multi-specific Antibodies
Identification and characterization of new broadly neutralizing and potent HIV-1-antibodies by Env-specific B cell sorting
The dual aptamer approach : rational design of a high-affinity FAD aptamer
Development of conformation specific Amyloid-beta antibodies
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Humans naturally acquire cross-specific anti-glycan antibodies
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neutralizing antibodies as tools for structure-based vaccine design
Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Development of conformation specific Amyloid-β [Amyloid-beta] antibodies
Protection from cytomegalovirus infection by glycoprotein-specific monoclonal antibodies
Bi- and Multi-specific Antibodies
Identification and characterization of new broadly neutralizing and potent HIV-1-antibodies by Env-specific B cell sorting
The dual aptamer approach : rational design of a high-affinity FAD aptamer
Development of conformation specific Amyloid-beta antibodies
Kinetics of Nucleo- and Spike Protein-Specific Immunoglobulin G and of Virus-Neutralizing Antibodies after SARS-CoV-2 Infection
Protective capacity of neutralizing and non-neutralizing antibodies against glycoprotein B of cytomegalovirus
Humans naturally acquire cross-specific anti-glycan antibodies
Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neutralizing antibodies as tools for structure-based vaccine design
Protection from Cytomegalovirus Infection by Glycoprotein-specific Monoclonal Antibodies
Development of conformation specific Amyloid-β [Amyloid-beta] antibodies